Global Angiotensin Receptor Blockers (ARBs) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Angiotensin Receptor Blockers (ARBs) Market Research Report 2024
Angiotensin II receptor blockers (ARBs), also known as angiotensin II receptor antagonists, AT1 receptor antagonists or sartans, are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors, preventing the binding of angiotensin II.
According to Mr Accuracy reports’s new survey, global Angiotensin Receptor Blockers (ARBs) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Angiotensin Receptor Blockers (ARBs) market research.
Key manufacturers engaged in the Angiotensin Receptor Blockers (ARBs) industry include Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Angiotensin Receptor Blockers (ARBs) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Angiotensin Receptor Blockers (ARBs) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Angiotensin Receptor Blockers (ARBs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Segment by Type
Valsartan
Telmisartan
Losartan
Irbesartan
Azilsartan
Olmesartan
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Angiotensin Receptor Blockers (ARBs) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Angiotensin Receptor Blockers (ARBs) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Angiotensin Receptor Blockers (ARBs) market research.
Key manufacturers engaged in the Angiotensin Receptor Blockers (ARBs) industry include Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Angiotensin Receptor Blockers (ARBs) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Angiotensin Receptor Blockers (ARBs) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Angiotensin Receptor Blockers (ARBs) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Segment by Type
Valsartan
Telmisartan
Losartan
Irbesartan
Azilsartan
Olmesartan
Segment by Application
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Angiotensin Receptor Blockers (ARBs) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices